Phaseline

Companies › Daré Bioscience

Daré Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DARE-HPV
Lopinavir/ritonavir combination (12:1 ratio) in vaginal capsule formulation
–Phase 2Human Papilloma Virus (HPV)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07601074DARE-HPVPhase 2Human Papilloma Virus (HPV)Infectious diseaseOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Frantz Viral Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.